Innovative Treatments for Blood Cancer and Inflammatory Eye Diseases

Company PresentationRead More

Senaste nytt

Our Projects

We develop innovative treatments for diseases with significant medical needs, such as blood cancer and inflammatory eye diseases. Our project portfolio includes both small, orally and topically active immunomodulatory molecules, as well as antibody-based immunotherapy.

Fully owned projects

    Discovery
    Preclinical
    Phase I
    Phase II
    Phase III

Hematological malignancies

Inflammatory eye disorders

Licensed projects

    Discovery
    Preclinical
    Phase I
    Phase II
    Phase III

Solid tumors

Financial Calendar

  1. Interim Report Jan-Sep 2026

  2. Year-end Report 2026

  3. Interim Report Jan-Mar 2027

View the Calendar

Share Information

  • Ticker symbol: ACTI
  • Marketplace: NASDAQ OMX Nordic Exchange (Stockholm)
  • Listed since: 1986
  • Shareholders: approximately 15,700
  • Number of ordinary shares: 26,360,671
  • Nominal value: 0.5164
To Investors

Financial Reports

All Reports

About Us

Our goal is to develop new medicines for the improved treatment of diseases with significant medical needs. Our projects are based on extensive documentation and scientific expertise.

Read more about us